Oncology
Audio Journal of Oncology Volume 16 Number 11
Scientific Editors: George Canellos (Boston), Pat Price (Manchester), Gianni Bonadonna (Milan), Gordon McVie (Milan)
Sarah Maxwell and Peter Goodwin report from: American Society of Clinical Oncology Annual Meeting, May 30-June 3, 2008, Chicago
In this edition:
1. Zoledronic Acid Reduces Recurrence In Early-Stage Breast Cancer
Michael Gnant, Medical University of Vienna, Austria
ABSTRACT: LBA4
2. Bevacizumab Slows Progression In Advanced Breast Cancer
David Miles, Mount Vernon Cancer Centre, London
ABSTRACT: LBA 1011
3. Discussion: Zoledronic Acid; Bevacizumab in Breast Cancer
Eric Winer, Dana-Farber Cancer Institute, Boston
ABSTRACT: LBA 4 & LBA 1011
4. Oral Capecitabine: Not For Older Patients with Early Breast Cancer
Hyman Muss, University of Vermont, Burlington
ABSTRACT: 507
5. Endometrial Cancer: Brachytherapy Is Better
Remi Nout, Leiden University Medical Center
ABSTRACT: LBA 5503
6. Adjuvant Gemcitabine Doubles Survival In Resected Pancreas Cancer
Helmut Oettle, Charité University, Berlin
ABSTRACT: LBA 4504
7. Everolimus Delays Metastatic Kidney Cancer Progression
Robert Motzer, Memorial Sloan-Kettering Cancer Center, New York
ABSTRACT: LBA 5026
8. Discussion: Gemcitabine For Pancreas Cancer; Brachytherapy for Endometrial Cancer
Nicholas Petrelli, Helen F Graham Cancer Center, Wilmington
ABSTRACTS: LBA 5503; LBA 4504; LBA5026
Buy Audio Journal of Oncology Digital Copy
Order Audio Journal of Oncology CD
Audio Journal of Oncology Volume 16 Number 10
Scientific Editors: George Canellos (Boston), Pat Price (Manchester), Gianni Bonadonna (Milan), Gordon McVie (Milan)
Commenting Expert: Michael Untch, HELIOS Klinikum, Berlin
In this edition Peter Goodwin and Sara Freeman report from:
European Breast Cancer Conference, Berlin, April 15-19, 2008;
Chemotherapy Foundation Symposium, November 6-10, 2007, New York;
9th European Congress: Perspectives in Lung Cancer, Turin, March 14-15, 2008;
The Lancet, New England Journal of Medicine
In this edition:
1. Lymphoma Immunotherapy: Anti-CD-80 Therapy With Galiximab
Myron Czuczman, Roswell Park Cancer Institute, Buffalo NY
Chemotherapy Foundation
2. Esophagogastric Cancer: Capecitabine First Line?
George Canellos, Dana-Farber Cancer Institute, Boston
N Engl J Med 358:1
3. Mammography: As Good For Older Patients
Jacques Fracheboud, Erasmus Medical Center, Rotterdam
EBCC , Berlin
4. Mammography: Three Year Interval Justified
Roger Blamey, Nottingham City Hospital
5. Mammography Assessed
Michael Untch, HELIOS Klinikum, Berlin
6. Colorectal Cancer: Add Chemo To Liver Mets Resection?
George Canellos, Dana-Farber Cancer Institute, Boston
Lancet 371:1007
7. Bevacizumab: New Standard for Non-Small Cell Lung Cancer?
Christian Manegold, Heidelberg University Medical Center, Manheim and Nick Thatcher, Christie Hospital, Manchester
European Lung Cancer Congress, Turin
8. Smoking And Death in India
George Canellos, Dana-Farber Cancer Institute, Boston
N Engl J Med 358:1137
Buy Audio Journal of Oncology Digital Copy
Order Audio Journal of Oncology CD
Audio Journal of Oncology Volume 16 Number 9
Scientific Editors: George Canellos (Boston), Pat Price (Manchester), Gianni Bonadonna (Milan), Gordon McVie (Milan)
Commenting Expert: Emiel Rutgers, Netherlands Cancer Institute, Amsterdam
In this edition:
1. Lapatinib: Targets Breast Cancer Stem Cells?
Angel Rodriguez, Baylor College, Houston
2. No Help Adding Neoadjuvant Capecitabine
Gunter von Minckwitz, German Breast Group, Neu-Isenberg
3. MRI Aids Breast Surgery Planning
David Martinez-Cecilia, University Hospital Reina Sofia, Córdoba
4. Aromatase Inhibitors: No Extra Heart Risk
Alain Monnier, Centre Hospitalier de Belfort, Montbéliard
5. NAB Paclitaxel For Metastatic Breast Cancer?
William Gradishar, Northwestern University, Chicago
Peter Goodwin and Sara Freeman interview conference speakers in Berlin regarding lapatinib’s apparent effect on breast cancer “stem cells”; the lack of additional benefit from adding capecitabine to standard neoadjuvant chemotherapy; evidence that MRI improves surgical planning for breast cancer; news that aromatase inhibitors do not add to cardiovascular risk when used in adjuvant therapy instead of tamoxifen; and (from a satellite symposium) an assessment of the role of nanoparticle albumin-bound paclitaxel in therapy for metastatic breast cancer.
Audio Journal of Oncology Volume 16 Number 8
Scientific Editors: George Canellos, Pat Price, Gordon McVie, Gianni Bonadonna
In this edition:
Bevacizumab and Survival in Metastatic Breast Cancer
Source: N Engl J Med 357:26
George Canellos, Dana-Farber Cancer Institute, Boston
Progresson-free survival, but not overall survival, was extended in patients with metastatic breast cancer who were randomly assigned to receive paclitaxel with bevacizumab as compared with paclitaxel alone.
Risks From Stopping Cancer Trials Early
Source: Annals of Oncology, April 9th, 2008
Giovanni Apolone, Mario Negri Institute, Milan
Stuart Pocock, London School of Hygiene and Tropical Medicine
New research highlights the dangers of stopping cancer clinical trials early following interim analysis before originally planned sample sizes have been reached, especially when surrogate end points are used.
Front Line Therapy in Non-Small Cell Lung Cancer
Nick Thatcher
There is a proven benefit in survival if you give your patients cis-platinum based chemotherapy after resection for non-small cell lung cancer. Nick Thatcher emphasized this fact at the beginning of his talk in Turin about front line therapy for non-small cell lung cancer. He went on to discuss optimizing therapy with respect to histology, performance status and the addition of targeted agents. Peter Goodwin interviewed him about his recommendations.
Bevacizumab: New Standard for Non-Small Cell Lung Cancer?
Christian Manegold
Nick Thatcher
Nick Thatcher, Christie Hospital, Manchester
Is bevacizumab a new standard of care for patients with unresectable non-small cell lung cancer who have good performance status? This question was raised in a debate at the European Congress on Lung Cancer held in Turin. Christian Manegold provided delegates with evidence from the AVAil and ECOG 4599 studies which underpin current approval of this anti-vascular endothelial growth factor (VEG-F) antibody. Nick Thatcher pointed out the limitations. They both talked with Peter Goodwin.
Audio Journal of Oncology in Advance - March 15th, 2008
Volume 16 Number 6 (March 15th, 2008) reporting from:
4th European Congress on Hematologic Malignancies (February 22-24, 2008, Paris)
American Society of Hematology Annual Meeting (December 8-11, 2007 Atlanta)
Chemotherapy Foundation Symposium, November 7-10, 2007, New York
David Maloney
Nonmyeloablative Alogeneic Transplants Ready for Prime-Time in Follicular Lymphoma?
Allogeneic transplantation is now a good option for treating some patient groups with follicular lymphoma. David Maloney explained to Peter Goodwin in Paris how his group has harnessed graft-versus-tumor effect by using nonmyeloablative conditioning without causing unacceptable risks of graft-versus-host disease.
Audio Journal of Oncology in Advance - March 1st, 2008
Volume 16 Number 5 (March 1st, 2008) reporting from:
4th European Congress on Hematologic Malignancies (February 22-24, 2008, Paris)
Gastrointestinal Cancers Symposium (January 25-27, 2008, Orlando)
American Society of Hematology Annual Meeting (December 8-11, 2007 Atlanta)
Richard Stone
George Canellos
Dasatinib: Durable Responses in Chronic Myeloid Leukemia
COMMENT: George Canellos, Dana-Farber Cancer Institute, Boston
Data released at the ASH conference show that dasatinib has given durable responses in patients with chronic phase chronic myeloid leukemia for whom imatinib has failed, or who cannot tolerate imatinib. In Atlanta Richard Stone discussed his findings with Derek Thorne, who then asked George Canellos to reflect on them.
“Total Therapy” Possible Cure For Multiple Myeloma?
Bart Barlogie
BART BARLOGIE, University of Arkansas, Little Rock
A treatment known as “total therapy” could cure many patients with multiple myeloma, conference-goers have just heard. The targeted drugs thalidomide and bortezomib, coupled with tandem autologous transplants, are used by Arkansas-based Bart Barlogie. In Paris he told Peter Goodwin about their success.
Combinations and Targeted Agents: Better Survival in Mantle Cell Lymphoma
Martin Dreyling
MARTIN DREYLING, University Hospital Grosshaden, Munich
Since the 1970s therapies for mantle cell lymphoma have greatly extended life, Martin Dreyling told conference delegates in Paris. He gave Peter Goodwin his latest data on combination therapy using the antibody, rituximab, and the emerging rôles of other targeted agents.
Chronic Lymphocytic Leukemia After Fludarabine Failure
John Gribben
JOHN GRIBBEN, Bartholemews Hospital, London
New promise for treating chronic lymphocytic leukemia is arising from combining antibody therapies rituximab and alemtuzumab with new drugs such as lenalidomide alongside standard fludarabine therapy. At the Paris symposium John Gribben gave Peter Goodwin the latest details.
Multiple Myeloma: Towards A Chronic Disease With Cure On The Horizon
Kenneth Anderson
KENNETH ANDERSON, Dana-Farber Cancer Institute, Boston
Multiple myeloma may soon be considered a chronic disease with cure on the horizon, thanks to an array of novel therapies which are turning prospects around for this malignancy. So said Kenneth Anderson at the European meeting in Paris. He explained to Peter Goodwin how a number of molecular and other therapies are changing the prospects for this disease.
Tony Gershlick, University of Leicester
Adnan Kastrati, Deutsches Herzzentrum, Munich
Brian Greenwood, London School of Hygiene and Tropical Medicine
